Skip to main content

Drug Interactions between Arixtra 7.5 mg/dose and Xiaflex

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

fondaparinux collagenase clostridium histolyticum

Applies to: Arixtra 7.5 mg/dose (fondaparinux) and Xiaflex (collagenase clostridium histolyticum)

MONITOR: The safety and efficacy of collagenase clostridium histolyticum in patients currently receiving, or within 7 days of receiving, anticoagulant medications other than low-dose aspirin (e.g., up to 150 mg/day) is unknown. Theoretically, the risk of bleeding complications may be increased. In clinical trials, 70% of collagenase clostridium histolyticum-treated patients developed an ecchymosis/contusion and 38% developed an injection site hemorrhage.

MANAGEMENT: Collagenase clostridium histolyticum should be used with caution in patients receiving or within 7 days of receiving anticoagulants (except for low-dose aspirin), platelet inhibitors, or thrombolytic agents.

References

  1. "Product Information. Xiaflex (collagenase clostridium histolyticum)." Auxilium Pharmaceuticals Inc (2010):

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer